Project Four 2029 Launches Legal Case for Federal Cannabis Rescheduling

Coalition Structure and Timeline

Project Four 2029 aims to deliver a complete administrative record to the DEA by December 2028, eighteen months ahead of the 2029 target date. The coalition's founding statement says the project will coordinate research submissions, public comments, and legal briefs from industry associations, patient advocacy groups, and academic institutions. A formal petition for rescheduling? Filed no later than Q1 2029.

The coalition includes representatives from state-licensed operators, medical cannabis patient networks, and tax-reform advocacy groups focused on IRC §280E repeal. On a strict reading of the Controlled Substances Act, the DEA retains sole authority to initiate or respond to rescheduling petitions. Still, the coalition believes a coordinated evidentiary submission will compel agency action.

Legal Strategy and Evidentiary Focus

The project's legal framework centers on compiling peer-reviewed medical evidence, state-level safety data, and economic impact analyses that address the five-factor test under 21 U.S.C. §811(c). That statutory test requires the DEA to evaluate abuse potential, scientific evidence of pharmacological effect, current scientific knowledge, history and current pattern of abuse, and scope, duration, and significance of abuse.

Project Four 2029 will fund original research on cannabis's accepted medical use, a threshold requirement for any schedule below Schedule I. The coalition's committed to publishing all submissions in a public docket to preempt claims of incomplete administrative records, a procedural weakness that derailed prior rescheduling efforts.

Tax and Compliance Implications

Rescheduling to Schedule III would eliminate the IRC §280E tax burden that currently prohibits state-licensed cannabis businesses from deducting ordinary business expenses. Under §280E, any business trafficking in Schedule I or II controlled substances can't claim federal tax deductions for rent, payroll, or marketing costs. That creates effective tax rates exceeding 70 percent for many operators.

If cannabis moves to Schedule III, the tax treatment shifts overnight—operators gain access to standard COGS deductions and can deduct operating expenses like any other business, fundamentally altering the economics of legal cannabis.

Coalition estimates peg §280E repeal at a $3.2 billion annual reduction in federal tax burden on the U.S. cannabis industry, based on 2025 revenue figures. For full background on this issue, see the CannIntel topic hub on federal cannabis rescheduling.

Political and Regulatory Landscape

The 2029 target date aligns with the start of a new presidential term, which the coalition views as a strategic window for regulatory action. DEA's 2024 decision to maintain Schedule I status followed a divided public comment period and conflicting recommendations from the Department of Health and Human Services. Project Four 2029 leadership stated that the new initiative will avoid the procedural missteps that allowed the DEA to defer action in prior cycles.

Funding sources? Undisclosed. But the coalition indicated it'll operate as a 501(c)(4) social welfare organization, allowing it to engage in lobbying without donor disclosure requirements. That structure mirrors the approach used by other drug-policy reform groups that have successfully petitioned for clemency and sentencing reforms.

Next milestone: coalition members expect to publish a preliminary evidentiary index by October 2026, outlining the research gaps the project will address over the next two years.